{"id":4558,"date":"2019-03-27T16:52:36","date_gmt":"2019-03-27T11:22:36","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4558"},"modified":"2023-04-04T10:52:52","modified_gmt":"2023-04-04T05:22:52","slug":"alzheimers-drug-fails-is-it-time-to-move-on","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/alzheimers-drug-fails-is-it-time-to-move-on","title":{"rendered":"Alzheimer’s drug fails! Is it time to move on?"},"content":{"rendered":"\n

Alzheimer\u2019s<\/strong> is one of the diseases which are irreversible and untreatable. With causes still unknown adds to the further conundrum.  But for more than two decades now Scientists from everywhere have been working on the \u201camyloid hypothesis<\/strong>“. It has been a long-standing theory that brains of the people affected with Alzheimer\u2019s<\/a> disease have clumps of amyloid-\u03b2 (A\u03b2) <\/strong>in the forms of senile<\/strong> plaques <\/strong>deposited in the brain tissues. These A\u03b2-peptide <\/strong>gets released into the space between brain cells after the enzymes \u03b2-secretase<\/strong> and \u03b3-secretase <\/strong>cleaves off Amyloid precursor protein (APP) <\/strong>present within the cell giving rise to amyloid- \u03b2 fragments. <\/p>\n\n\n\n

One in 10 people (10 percent) aging 65 and older are living with Alzheimer\u2019s dementia. More women than men are reported to suffer from Alzheimer\u2019s or other dementias<\/a>.<\/strong> Almost two-thirds of Americans with Alzheimer\u2019s are women. Out of 5.5 million people aged 65 and older with Alzheimer\u2019s in the United States, 3.4 million are women and 2.0 million are men.<\/p>\n\n\n\n

And, now the news of halting of two Phase 3 clinical trials of Aducanumab, <\/strong>meant to attack Alzheimer, by Biogen and <\/strong>its Japanese partner Eisai<\/strong> has crushed the hopes of beating the memory-destroying disease. All the drugs so far developed to target amyloid-\u03b2 like Eli Lilly’s solanezumab, <\/strong>Pfizer\u2019s bapineuzumab, <\/strong>and Merck\u2019s BACE inhibitor verubecestat<\/g> <\/strong>failed miserably during their clinical trials. For Aducanumab<\/strong> it was altogether a different story not to be missed it was the most propitious candidate among the others. With zero to only a little failure in previous trials, it was the most looked-after as the company was running its simultaneous two Phase III trials. The decision to halt the trial did not come out of any safety concern but due to the zero results in Phase 3.
The news of Aducanumab <\/strong>being dead affected Biogen\u2019s stock as it dropped by a whopping 30% wiping off more than USD 18 billion<\/strong>. Biogen had considered it an upcoming gem of a drug not because of unmet medical need and huge market size but also because it could be a major key-driver. With biogen\u2019s stock what crashed is the hope of millions of patients and families affected by Alzheimer<\/a>. <\/p>\n\n\n\n

The failures here do confirm the complex nature of the disease in question. It might look like the amyloid hypothesis <\/strong>has failed.<\/strong> But Biogen and Eisai haven\u2019t relinquished yet. Eisai has started to move forward with Phase 3 trial of its another Alzheimer\u2019s <\/a>drug BAN2401. <\/strong>The failure of drugs to attack amyloid-\u03b2 <\/strong>doesn\u2019t in any way meant that the hypothesis is false. And the new focus will be on testing the people who are still well. The diagnosis of Alzheimer <\/a>even when the mild symptoms are visible is still too late to target amyloid-\u03b2 as the by then the build of amyloid would have led to the formation of tau-containing neurofibrillary<\/strong> tangles killing more brain cells. So focus on an early diagnosis is what is required looking at the current scenario of the disease. <\/p>\n","protected":false},"excerpt":{"rendered":"

Alzheimer\u2019s is one of the diseases which are irreversible and untreatable. With causes still unknown adds to the further conundrum.  But for more than two decades now Scientists from everywhere have been working on the \u201camyloid hypothesis“. It has been a long-standing theory that brains of the people affected with Alzheimer\u2019s disease have clumps of […]<\/p>\n","protected":false},"author":1,"featured_media":4563,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":2,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[2998,1407,7145,72,2991,2997,2993,3001,2999,830,1158,2996,1541,3003,395,460,2992,3000,2994,2995],"industry":[17225],"therapeutic_areas":[17229,17245],"class_list":{"0":"post-4558","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","6":"hentry","7":"category-snippets","8":"tag-aducanumab","9":"tag-alzheimer","10":"tag-alzheimers-disease-market","11":"tag-alzheimers-disease","12":"tag-amyloid-hypothesis","13":"tag-amyloid-precursor-protein-app","14":"tag-amyloid--a","15":"tag-a-peptide","16":"tag-ban2401","17":"tag-biogen","18":"tag-dementia","19":"tag-dementias","20":"tag-eisai","21":"tag-mentalhealth","22":"tag-merck","23":"tag-pfizer","24":"tag-senile-plaques","25":"tag-tau-protein","26":"tag--secretase","28":"industry-pharmaceutical","29":"therapeutic_areas-central-nervous-system","30":"therapeutic_areas-neurology"},"acf":[],"yoast_head":"\nAlzheimer's drug fails! Is it time to move on? - DelveInsight<\/title>\n<meta name=\"description\" content=\"the news of halting of two Phase 3 clinical trials of Aducanumab meant to attack Alzheimer by Biogen and its Japanese partner Eisai has crushed the hopes...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-drug-fails-is-it-time-to-move-on\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alzheimer's drug fails! Is it time to move on? - DelveInsight\" \/>\n<meta property=\"og:description\" content=\"the news of halting of two Phase 3 clinical trials of Aducanumab meant to attack Alzheimer by Biogen and its Japanese partner Eisai has crushed the hopes...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-drug-fails-is-it-time-to-move-on\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-27T11:22:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-04T05:22:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021329\/Capture222-3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"745\" \/>\n\t<meta property=\"og:image:height\" content=\"670\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alzheimer's drug fails! Is it time to move on? - DelveInsight","description":"the news of halting of two Phase 3 clinical trials of Aducanumab meant to attack Alzheimer by Biogen and its Japanese partner Eisai has crushed the hopes...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/alzheimers-drug-fails-is-it-time-to-move-on","og_locale":"en_US","og_type":"article","og_title":"Alzheimer's drug fails! Is it time to move on? - DelveInsight","og_description":"the news of halting of two Phase 3 clinical trials of Aducanumab meant to attack Alzheimer by Biogen and its Japanese partner Eisai has crushed the hopes...","og_url":"https:\/\/www.delveinsight.com\/blog\/alzheimers-drug-fails-is-it-time-to-move-on","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-03-27T11:22:36+00:00","article_modified_time":"2023-04-04T05:22:52+00:00","og_image":[{"width":745,"height":670,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021329\/Capture222-3.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-drug-fails-is-it-time-to-move-on","url":"https:\/\/www.delveinsight.com\/blog\/alzheimers-drug-fails-is-it-time-to-move-on","name":"Alzheimer's drug fails! Is it time to move on? - DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-drug-fails-is-it-time-to-move-on#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-drug-fails-is-it-time-to-move-on#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021329\/Capture222-3.png","datePublished":"2019-03-27T11:22:36+00:00","dateModified":"2023-04-04T05:22:52+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"the news of halting of two Phase 3 clinical trials of Aducanumab meant to attack Alzheimer by Biogen and its Japanese partner Eisai has crushed the hopes...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/alzheimers-drug-fails-is-it-time-to-move-on"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-drug-fails-is-it-time-to-move-on#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021329\/Capture222-3.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021329\/Capture222-3.png","width":745,"height":670},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021329\/Capture222-3-300x270.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Aducanumab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Alzheimer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Alzheimer's Disease Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">amyloid hypothesis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Amyloid precursor protein (APP)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">amyloid-\u03b2 (A\u03b2)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">A\u03b2-peptide<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">BAN2401<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Biogen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Dementia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">dementias<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Eisai<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">mentalhealth<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">senile plaques<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">tau protein<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">\u03b2-secretase<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">\u03b3-secretase<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Aducanumab<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer's Disease Market<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">amyloid hypothesis<\/span>","<span class=\"advgb-post-tax-term\">Amyloid precursor protein (APP)<\/span>","<span class=\"advgb-post-tax-term\">amyloid-\u03b2 (A\u03b2)<\/span>","<span class=\"advgb-post-tax-term\">A\u03b2-peptide<\/span>","<span class=\"advgb-post-tax-term\">BAN2401<\/span>","<span class=\"advgb-post-tax-term\">Biogen<\/span>","<span class=\"advgb-post-tax-term\">Dementia<\/span>","<span class=\"advgb-post-tax-term\">dementias<\/span>","<span class=\"advgb-post-tax-term\">Eisai<\/span>","<span class=\"advgb-post-tax-term\">mentalhealth<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">senile plaques<\/span>","<span class=\"advgb-post-tax-term\">tau protein<\/span>","<span class=\"advgb-post-tax-term\">\u03b2-secretase<\/span>","<span class=\"advgb-post-tax-term\">\u03b3-secretase<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Mar 27, 2019","modified":"Updated on Apr 4, 2023"},"absolute_dates_time":{"created":"Posted on Mar 27, 2019 4:52 pm","modified":"Updated on Apr 4, 2023 10:52 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4558"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4558\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4563"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4558"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4558"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4558"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4558"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}